v3.25.4
Segment Information (Tables)
12 Months Ended
Dec. 31, 2025
Segment Reporting [Abstract]  
Schedule of Segment Reporting Information, by Segment
Significant segment expenses are included in the table below and represent direct and indirect research and development expenses by project for the years ended December 31, 2025, 2024 and 2023 were as follows (in thousands):
Years Ended December 31,
202520242023
Direct research and development expense:
Cadisegliatin11,434 6,026 10,182 
Other projects*
(1,258)490 676 
Indirect research and development expense†7,685 5,030 2,737 
Total research and development expense$17,861 $11,546 $13,595 
*
Includes HPP737 and azeliragon
Includes share-based compensation